Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;64(4):968-73.
doi: 10.1016/j.jhep.2015.12.021. Epub 2016 Jan 11.

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

Thomas F Baumert  1 , Catherine Schuster  2 , François-Loïc Cosset  3 , Jean Dubuisson  4 , Maike Hofmann  5 , Norbert Tautz  6 , Mirjam B Zeisel  2 , Robert Thimme  5
Affiliations
Review

Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses

Thomas F Baumert et al. J Hepatol. 2016 Apr.

Abstract

Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.

Keywords: Hepatitis C virus; Immune responses; Liver disease; Meeting report; Molecular virology; Resistance; Therapy; Treatment; Vaccine; Viral hepatitis; Virus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no competing financial interests. TFB has served as advisor for Gilead, Biotest and Vironexx. Inserm, the University of Strasbourg and Genovac/Aldevron Freiburg have filed a patent application on monoclonal anti-claudin1 antibodies for the inhibition of hepatitis C virus infection (US Patent # 8,518,408; WO2010034812; PCT/EP 08 305 597 0).

References

    1. Chung RT, Baumert TF. Curing chronic hepatitis C – the arc of a medical triumph. N Engl J Med. 2014;370:1576–1578. - PubMed
    1. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87–S99. - PubMed
    1. Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci. 2015;129:63–107. - PubMed
    1. Murray CL, Jones CT, Rice CM. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev. 2008;6:699–708. - PMC - PubMed
    1. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011;19:95–103. - PubMed

Publication types

Substances

LinkOut - more resources